Qilu Pharmaceutical

Qilu Pharmaceutical is dedicated to maintaining human health, committed to meeting societal needs, and leveraging advanced science and technology to develop drugs for the treatment of common diseases, frequently occurring diseases, and various other serious conditions that endanger human health.
Headquartered in Jinan City, Shandong Province, the company is a large-scale comprehensive modern pharmaceutical enterprise in China, specializing in the development, production, and sales of pharmaceutical preparations and active pharmaceutical ingredients (APIs) for treating tumors, cardiovascular and cerebrovascular diseases, anti-infective diseases, psychiatric disorders, neurological diseases, and ophthalmic diseases.
The company has established strict and standardized quality control institutions and a comprehensive quality assurance system, and is among the first batch of enterprises to receive GMP certification from the National Medical Products Administration (NMPA). Among these, the non-sterile APIs (fermentation and chemical synthesis), sterile APIs, and various formulations have passed the certification of drug regulatory authorities in the United States, the European Union, Australia, the United Kingdom, South Africa, and other countries and regions.
The company's product structure is scientifically complete and well-integrated, with more than 270 products on the market, characterized by a wide therapeutic range and product series. Thanks to excellent product quality and a service philosophy of wholehearted dedication to customers, Qilu has established its brand in the pharmaceutical field, with a sales network covering major provinces and cities across China and exported to North America, the EU, Japan, Australia, and other regions, presenting a thoroughly trustworthy sincerity to China and the world through outstanding service.